Opioid Analgesic Chronic Pain Studies Pose Challenge For FDA
Executive Summary
FDA will be asking the Anesthetic & Life Support Drugs Advisory Committee for input into the appropriate inclusion criteria for studies of opioid analgesics in chronic pain.
You may also be interested in...
Homogeneous Opioid Trial Populations Could Simplify, Improve Data – Cmte
Limiting opioid trial populations to specific pain syndromes could improve safety and efficacy evaluations of the analgesics, FDA's Anesthetic & Life Support Drugs Advisory Committee suggested
Homogeneous Opioid Trial Populations Could Simplify, Improve Data – Cmte
Limiting opioid trial populations to specific pain syndromes could improve safety and efficacy evaluations of the analgesics, FDA's Anesthetic & Life Support Drugs Advisory Committee suggested
FDA Opioid Analgesics Risk Management Models Include Stadol NS, Actiq
An FDA advisory committee will consider whether risk management models used for Bristol-Myers Squibb's Stadol NS, Sanofi-Synthelab's Talwin NX and Cephalon's Actiq should be more generally applied to other opioid analgesics.